The Imminent danger of Lp(a): Time to face the Challenge
EAS endorsed satellite meetingAgenda - May 24, 2019 - Maastricht, The Netherlands
The symposium is an initiative of the Dutch Atherosclerosis Society (DAS) in collaboration with the Physicians’ Academy for Cardiovascular Education foundation (PACE-CME) targeted on an international audience of clinicians and researchers with an interest in atherosclerosis & CVD.
The symposium will be fully dedicated to exploring the emerging role of Lipoprotein (a) in the development of cardiovascular disease and as a target for current and future therapies.
The meeting venue is:
- Bonbonnière, a theatre downtown the city of Maastricht (Address: Achter de Comedie 1, 6211 GZ Maastricht))
Session 1: Pathophysiology
- (Hi)story of Lp(a) into the CV arena - Florian Kronenberg, Innsbruck, Austria
- Lp(a) and calcification in aortic stenosis - Kang Zheng, Brigham and Women’s Hospital, Boston, MA, USA (also on behalf Marc Dweck, Edinburgh, United Kingdom)
- Lp(a) and immune metabolism - Jeffrey Kroon, Amsterdam, The Netherlands
Session 2: Epidemio-Genetics
- Lp(a) (genetics/plasma) and CV morbidity and mortality - Pia Kamstrup, Copenhagen, Denmark
- Prevalence and relevance of Lp(a) in familial hypercholesterolemia - Børge Nordestgaard, Copenhagen, Denmark
- Lp(a) apheresis and CVD risk (modulation) - Elisa Waldmann, Germany
Session 3: Lab challenges
- Structural determinants of Lipoprotein(a) pathogenicity - Marlys Koschinsky ,London, ONT, Canada
- Are we ready for prime-time assay standardisation? - Santica Marcovina, Seattle, WA, USA
- LDL vs Lp(a) cholesterol: confounding - Calving Yeang, San Diego, CA, USA
Session 4: Therapy
- Estimated impact of Lp(a) modulation on CVD-risk - Brian Ference, Cambridge, United Kingdom
- Lp(a) contribution to PCSK9-ab benefit in ODYSSEY - Wouter Jukema, Leiden, The Netherlands
- Phase II data, followed by NHLBI recommendation - Sam Tsimikas, San Diego, CA, USA
To register for the satellite meeting, please use this link, or the link at the bottom of this page
Early-bird registration ends Friday, April 26
Normal registration fee from April 27 - May 17
Late registration fee from May 17 - May 24
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
The meeting is funded via educational grants provided by Amgen and Novartis.